Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Treatment of walking impairment in multiple sclerosis with dalfampridine.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Gilenya prescribing information
Medical marijuana: clearing away the smoke.
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial.
MP2RAGE Multiple Sclerosis Magnetic Resonance Imaging at 3 T.
Multiple sclerosis: Risk of comorbid inflammatory diseases in MS might not be genetically determined.
Rituximab: Don't Count It Out as MS Treatment
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis.
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis

Pages